CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)

CytomX Therapeutics, Inc.

Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.
Cash $346.7M (Dec 31: $137.1M) includes $234.2M net from March equity offering; runway to at least 2H 2028.
Varseta-M dose optimization enrollment completed (40 patients); data update in 2H 2026 to inform monotherapy dose and potential registrational trial in late-line CRC.
Varseta-M + bevacizumab Phase 1 combo underway; initial data by 1H 2027; Phase 1/2 chemo combo starts 2H 2026.
CX-801 (PROBODY IFNα2b) Phase 1 combo with Keytruda enrolling third dose level; initial combo data expected end 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CytomX Therapeutics, Inc. reported for the quarter ended March 31, 2026 results: revenue 10.3 million.

Period: for the quarter ended March 31, 2026
Revenue: 10.3 million
Result: reported results

Exact text from the filing

Total revenue was $10.3 million for the quarter ended March 31, 2026, compared to $50.9 million for the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211920

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.